Seasonal Temperature Impacts Patients’ Laboratory Results
|
By LabMedica International staff writers Posted on 23 Dec 2021 |

Image: Schematic graphics showing how variation in common laboratory test results caused by ambient temperature (Photo courtesy of Cell Press)
Every year, 13 billion laboratory tests are performed in the USA, nearly 800 million in the UK, and many more worldwide. Test results provide critical data on clinically important changes in patient physiology.
These test including acute variations in plasma volume, body temperature, circadian rhythms, but can also vary for more idiosyncratic reasons from one phlebotomy to the next, like differences in technique or sample processing. The effect of ambient temperature on the day blood is drawn has been explored.
Health scientists at the University of California, Berkeley (Berkeley, CA, USA) and from the University of Chicago (Chicago, IL, USA) analyzed a large dataset of test results from 2009 to 2015, spanning several climate zones. In a sample of more than four million patients, they modeled more than two million test results as a function of temperature. They measured how day-to-day temperature fluctuations affected results, over and above the patients’ average values, and seasonal variation. In the dataset were 4,877,039 individuals who had laboratory result data. Daily temperature ranges from a low of −28 °C (Fairbanks, AK, USA; February 16, 2011) to 49 °C (Yuma, AZ, USA; July 23, 2014).
The investigators reported that the results showed that temperature affected more than 90% of individual tests and 51 of 75 assays, are significantly affected by temperature, including measures of kidney function (increased creatinine, urea nitrogen, and urine specific gravity), cellular blood components (decreased neutrophils, erythrocytes, and platelets), and lipids (increased high-density lipoprotein [HDL] and decreased total cholesterol, triglycerides, and low-density lipoprotein [LDL]). These small, day-to-day fluctuations did not likely reflect long-term physiological trends. For example, lipid panels checked on cooler days appeared to suggest a lower cardiovascular risk, leading to almost 10% fewer prescriptions for cholesterol-lowering drugs called statins to patients tested on the coolest days compared to the warmest days, even though these results probably did not reflect stable changes in cardiovascular risk.
One practical implication of the study is that laboratories could statistically adjust for ambient temperature on the test day when reporting laboratory results. Doing so could reduce weather-related variability at a lower cost than new laboratory assay technology or investments in temperature control in transport vans. In practice, decisions on adjustment would need to be at the discretion of the laboratory staff and the treating physician, potentially on a case-by-case basis.
Ziad Obermeyer, MD is the Distinguished Associate Professor of Health Policy and Management and first author of the study, said, “The textbook way of thinking about medical investigation is bench to bedside. First, we come up with a hypothesis, based on theory, then we test it with data. As more and more big data comes online, like the massive dataset of laboratory tests we used, we can flip that process on its head: discover fascinating new patterns and then use bench science to get to the bottom of it. I think this bedside-to-bench model is just as important as its better-known cousin because it can open up totally new questions in human physiology.”
The authors concluded that ambient temperature affects the results of many laboratory tests. These distortions, in turn, affect medical decision-making. Statistical adjustment in reporting is feasible and could limit undesired temperature-driven variability. The study was published on December 10, 2021 in the new journal MED.
Related Links:
University of California, Berkeley
University of Chicago
These test including acute variations in plasma volume, body temperature, circadian rhythms, but can also vary for more idiosyncratic reasons from one phlebotomy to the next, like differences in technique or sample processing. The effect of ambient temperature on the day blood is drawn has been explored.
Health scientists at the University of California, Berkeley (Berkeley, CA, USA) and from the University of Chicago (Chicago, IL, USA) analyzed a large dataset of test results from 2009 to 2015, spanning several climate zones. In a sample of more than four million patients, they modeled more than two million test results as a function of temperature. They measured how day-to-day temperature fluctuations affected results, over and above the patients’ average values, and seasonal variation. In the dataset were 4,877,039 individuals who had laboratory result data. Daily temperature ranges from a low of −28 °C (Fairbanks, AK, USA; February 16, 2011) to 49 °C (Yuma, AZ, USA; July 23, 2014).
The investigators reported that the results showed that temperature affected more than 90% of individual tests and 51 of 75 assays, are significantly affected by temperature, including measures of kidney function (increased creatinine, urea nitrogen, and urine specific gravity), cellular blood components (decreased neutrophils, erythrocytes, and platelets), and lipids (increased high-density lipoprotein [HDL] and decreased total cholesterol, triglycerides, and low-density lipoprotein [LDL]). These small, day-to-day fluctuations did not likely reflect long-term physiological trends. For example, lipid panels checked on cooler days appeared to suggest a lower cardiovascular risk, leading to almost 10% fewer prescriptions for cholesterol-lowering drugs called statins to patients tested on the coolest days compared to the warmest days, even though these results probably did not reflect stable changes in cardiovascular risk.
One practical implication of the study is that laboratories could statistically adjust for ambient temperature on the test day when reporting laboratory results. Doing so could reduce weather-related variability at a lower cost than new laboratory assay technology or investments in temperature control in transport vans. In practice, decisions on adjustment would need to be at the discretion of the laboratory staff and the treating physician, potentially on a case-by-case basis.
Ziad Obermeyer, MD is the Distinguished Associate Professor of Health Policy and Management and first author of the study, said, “The textbook way of thinking about medical investigation is bench to bedside. First, we come up with a hypothesis, based on theory, then we test it with data. As more and more big data comes online, like the massive dataset of laboratory tests we used, we can flip that process on its head: discover fascinating new patterns and then use bench science to get to the bottom of it. I think this bedside-to-bench model is just as important as its better-known cousin because it can open up totally new questions in human physiology.”
The authors concluded that ambient temperature affects the results of many laboratory tests. These distortions, in turn, affect medical decision-making. Statistical adjustment in reporting is feasible and could limit undesired temperature-driven variability. The study was published on December 10, 2021 in the new journal MED.
Related Links:
University of California, Berkeley
University of Chicago
Latest Clinical Chem. News
- Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
- New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
- Multi-Protein Blood Test Improves Staging of Alzheimer’s Disease
- Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury
- Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
- AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer
- Compact Prenatal Screening System Expands Access to Preeclampsia Testing
- Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Channels
Molecular Diagnostics
view channel
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







